In a recent reversal, operations abroad are hampering profit.
Indias First Healthcare, Beauty & Wellness Franchising Report launched by Franchise India at the Kno
Franchise India Holdings limited in association with Francorp and Medium Healthcare Consulting Pvt Ltd has organized a two day workshop on Business of Healthcare, Wellness and Beauty at Taj Lands End, Mumbai. On the occasion India’s First Healthcare, Wellness and Beauty Franchising Report was launched by Mr. Ratan Jalaan, Founder, Medium Healthcare Marketing and Mr. Sachin Marya, CEO & Publisher, Franchise India Holdings Limited.
Bafna Pharmaceuticals,shall be focussing mainly on life-style products, the company chariman and managing director, Mahaveer Chand, disclosed, in an exclusive interview with pharmaquest.biz
As domestic pharma and life science companies aggressively scale up their R&D capabilities to meet the rising demand for clinical research from global majors, they are back in the job market to scout and woo talent with attractive salary packages.
The distance between Big Pharma and the generic drugs business keeps getting narrower. Under a deal with an Indian drugs shop Strides Arcolab, Pfizer will add some 40 off-patent drugs, including many cancer medicines, to the list of products it sells in the U.S. Here’s a statement Pfizer put out describing the deal.
Ahmedabad-based Cadila Healthcare Ltd could well be the first Indian company to launch the H1N1 vaccine in India. It expects to bring its vaccine in the market by April 2010.
Pharmaceutical major Piramal Healthcare is planning to raise Rs 1,000 crore (Rs 10 billion) in the next 6-8 months, a senior company official said here on Thursday.
The year had just begun, when Pfizer announced its $68-billion deal to acquire Wyeth, in January. On its heels came Merck & Co's $ 41-billion deal to acquire Schering-Plough Corporation, in March.
Painkillers may help relieve pain, but as with most things, too much of the drugs is bad for health. Some learn it the hard way.
For the pharmaceutical sector, 2009 was a year when Indian manufacturing capabilities took centre stage. For the first time, global pharmaceutical giants like Pfizer and GlaxoSmithKline (GSK) came shopping for Indian manufacturers. Pharmaquest.biz recaps some of biggest inbound pharma deals this year.
Yet another year has also gone by. But the issues related to pharma and health sectors remain mostly unresolved, thanks to the lackadaisical manner in which the government looks at these issues. Several crucial files regarding policies and regulations related to these sectors are still stuck at various government departments with no sign of immediate disposal. The only silver lining on the otherwise gloomy horizon was the introduction of 'Transplantation of Human Organs Act, 1994' in Parliament at the fag end of the last session of Parliament.
Many shifting focus to emerging economies in struggle to stay afloatMajor Japanese pharmaceutical makers are expediting projects to construct plants and expand sales channels in emerging economies, such as China and India.
Its pharma's turn to take center stage. Here's a look back at the highs and lows of what happened in 2009.
The swine flu pandemic forced pharma groups to develop vaccines as quickly as possible but the market for such disease-resistant products has been booming for years.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy’s Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
The market has recently seen the re-rating of small companies in the FMCG and pharma sectors. FMCG players Dabur India and Emami witnessed the stocks of their recently-acquired companies, Fem Care Pharma and Zandu Pharma getting re-rated. Similarly, pharma companies, Cadila Care and Elder Pharma, have seen a lot of price action in the stocks of Zydus Wellness and Elder Health Care, respectively which were hived-off into independent companies respectively.
In a sector that is seeing more inbound acquisitions of late, the latest being the Hospira-Orchid deal, the zeal to pursue large outbound acquisitions would be restricted for some time at least.
2007 was the year that pharma fell in love with biologics, but as the saying goes, you can't love someone else before you love yourself. 2009 was the year pharma fell in love with itself.
India's pharmaceutical sector has stepped up its research & development expenditure in a bid to capture a larger market share in highly regulated and emerging markets.
Gujarat-based pharma companies are turning homewards, as their honeymoon period in the tax-free havens of hill states like Himachal Pradesh and Uttarakhand ends in March 2010.